Malaria
Drug research and approvals for malaria: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 58 studies of malaria are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 5 approved and 21 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 58
- Trials authorized in Canada: 0
- FDA orphan approvals: 5
- EU medicines: 2
Recruiting Now
Newest start dates first, of 58 recruiting on ClinicalTrials.gov ↗- A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum MalariaNCT07545681 · Phase 2 · GlaxoSmithKline · starts Oct 7, 2026
- Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community TransmissionNCT07246525 · Phase 4 · University of California, San Francisco · starts Sep 22, 2026
- Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali.NCT07758985 · Phase 1 · Medicines for Malaria Venture · starts Sep 14, 2026
- Non-invasive Malaria Diagnostic Data Collection in EthiopiaNCT07456969 · Not reported · Foundation for Innovative New Diagnostics, Switzerland · starts Aug 7, 2026
- First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy AdultsNCT07646353 · Phase 1 · GlaxoSmithKline · starts Jul 27, 2026
- PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in MaliNCT07675785 · Phase 2 · Sanaria Inc. · starts Jul 20, 2026
- Management of Severe Plasmodium Falciparum Malaria With Oral Artemisinin DerivativesNCT07935109 · Not reported · Centre Hospitalier de Saint-Denis · starts Jul 15, 2026
- Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT)NCT07749911 · Not reported · Clinton Health Access Initiative Inc. · starts Jul 14, 2026
- Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum…NCT07708714 · Phase 1 / Phase 2 · Children's Hospital Medical Center, Cincinnati · starts May 13, 2026
- Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe AdultsNCT07385287 · Phase 2 · Sanaria Inc. · starts May 4, 2026
Drug Pipeline
20 approved, 27 in phase 3, 15 in phase 2, 27 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Artesunate, Artemether, Lumefantrine, Amodiaquine, Pyrimethamine, Artenimol, Primaquine, Chloroquine, Mefloquine, Quinine, Atovaquone, Proguanil, Tafenoquine, Doxycycline anhydrous, Hydroxychloroquine, Quinidine, Halofantrine, Sulfadiazine, Artemotil, Artemisinin
- Sulfadoxine
- Phase 3 Dihydropteroate synthetase inhibitor
- Piperaquine
- Phase 3 Ferriprotoporphyrin IX inhibitor
- Pyronaridine
- Phase 3
- Rabies vaccine
- Phase 3 Biological vaccine - induces immune response
- Ivermectin
- Phase 3 Glutamate-gated chloride channel modulator
- Dapsone
- Phase 3 Dihydropteroate synthase 1 inhibitor
- Azithromycin
- Phase 3 Bacterial 70S ribosome inhibitor
- Chlorproguanil
- Phase 3
- Fosmidomycin
- Phase 3 1-deoxy-D-xylulose 5-phosphate reductoisomerase, apicoplastic inhibitor
- MATRIX-M1 adjuvant
- Phase 3
- Yellow fever vaccine
- Phase 3 Biological vaccine - induces immune response
- Retinol
- Phase 3
- Acetaminophen
- Phase 3 Cyclooxygenase inhibitor
- Cisplatin
- Phase 3 DNA inhibitor
- Cytarabine
- Phase 3 DNA inhibitor
- Prasterone
- Phase 3 Unknown
- Dexamethasone
- Phase 3 Glucocorticoid receptor agonist
- Albendazole
- Phase 3 Tubulin inhibitor
- Sulfalene
- Phase 3 Bacterial dihydropteroate synthase inhibitor
- Sulfamethoxazole
- Phase 3 Bacterial dihydropteroate synthase inhibitor
- Trimethoprim
- Phase 3 Bacterial dihydrofolate reductase inhibitor
- Tromethamine
- Phase 3 Unknown
- Mannitol
- Phase 3 Unknown
- Folic acid
- Phase 3
- Abamectin
- Phase 3
- Zinc ion
- Phase 3
- Artemisin
- Phase 3
- Artefenomel
- Phase 2
- Cipargamin
- Phase 2 P-type ATPase inhibitor
- Ganaplacide
- Phase 2
Showing the 30 furthest along of 69 in trials.
How Its Trials Ended
1,283 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 463 whose ending is known, 67% met their primary endpoint, 13% missed it and 21% stopped early.
- Completed, result not reported59046%
- Met its primary endpoint30824%
- Ongoing1199%
- Status unknown1119%
- Stopped: other or unclear625%
- Missed its primary endpoint605%
- Stopped: lack of efficacy101%
- Stopped: sponsor or business decision81%
- Stopped: enrollment or feasibility71%
- Stopped: safety50%
- Stopped: funding30%
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 26| May 26, 2020 | ArtesunateArtesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe… | Amivas Inc. | Approved |
| Jul 20, 2018 | KrintafelKRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are… | GlaxoSmithKline Intellectual Property Development Ltd. England | Approved |
| Apr 7, 2009 | CoartemTreatment of malaria in patients of 5 kg bodyweight or above with acute, uncomplicated malaria due to Plasmodium falciparum or mixed… | Novartis Pharmaceuticals | Approved |
| Aug 12, 2005 | Quinine SulfateTreatment of uncomplicated Plasmodium falciparum malaria | AR Holding Company, Inc. | Approved |
| Jul 24, 1992 | HalfanTreatment of adults who can tolerate oral medication and who have mild to moderate malaria caused by Plasmodium falciparum or Plasmodium… | SmithKline Beecham Pharmaceuticals | Approved |
| Oct 20, 2026 | Dual plasmepsin inhibitor against plasmepsin IX and…Treatment of malaria | Merck, Sharp & Dohme LLC | Designated |
| Jun 20, 2025 | 3S,4R,8R,9S,10S)-10-…Treatment of malaria | Eisai Inc. | Designated |
| Aug 15, 2022 | Ganaplacide and Lumefantrine fixed-dose combinationTreatment of Malaria | Novartis Pharmaceuticals Corporation | Designated |
| Dec 14, 2021 | (R)-N2-(4-cyclopropyl-5-fluoro-6-methylpyridin-2-yl)-N4-(1,…Treatment of malaria | Cadila Healthcare Limited | Designated |
| May 1, 2020 | CipargaminTreatment of malaria | Novartis Pharmaceuticals Corporation | Designated |
| Feb 11, 2020 | Pyronaridine tetraphosphateTreatment of Malaria | Collaborations Pharmaceuticals, Inc. | Designated |
| Mar 15, 2019 | MeplazumabTreatment of malaria | Jiangsu Pacific-Meinuoke Bio-pharmaceutical Co., Ltd. | Designated |
| Sep 27, 2018 | Fixed dose combination of pyronaridine tetraphosphate and…Treatment of malaria | Shin Poong Pharmaceutical Co., Ltd. | Designated |
| Sep 5, 2017 | ArtesunateTreatment of malaria | Guilin Pharmaceutical Co., Ltd. | Designated |
| Aug 18, 2017 | 2-(1,1-difluoroethyl)-5-methyl-N-[4-(pentafluoro-¿{6}-sulfan…Treatment of malaria | Paul Maher, MD | Designated |
Medicines Authorised in the EU
Newest first| Nov 22, 2021 | Artesunate AmivasArtesunate · orphan | Amivas Ireland Ltd | EMA ↗ |
| Oct 27, 2011 | EurartesimPiperaquine tetraphosphate;artenimol | Alfasigma S.p.A. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA